To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.
Also called NCT05075408
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 258 participants
- Sponsor
- Galderma R&D
- Registry
-
NCT05075408 -
2021-004766-35
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Hungary, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05075408. Randomized; double masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2024-01-04 (actual). Results posted on 2025-02-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
- Acronym
- NIKAIA 1
- Condition
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
- Intervention (Drug)
- Nemolizumab
- Intervention (Drug)
- Nemolizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Galderma R&D
Record details
- Record id
cardio:ct-nct05075408- Content hash
17e85f0514607b2ae3f42a48eaf5ac91c950c14341598922dbc8956b264f8a84